Apheris AI Access Timeline
Reviewed Strategic Signal records on Apheris’s AI access relationships, rights, and disclosed economics.
These selected timelines include reviewed registry records that explicitly name each organization in a participant field. A product, affiliate, or parent name alone does not establish participation. Coverage reflects Strategic Signal’s research sample. Records are ordered by original announcement date. A record may reflect later amendments or evidence updates.
Sep 29, 2026 · Data-rights qualified
AbbVie → Ginkgo Datapoints
A planned standardized dataset targeting 10,000 antibodies, combining proprietary antibody sequences contributed by AbbVie, argenx, Lundbeck, and Takeda with Ginkgo-generated developability assay measurements. Raw member sequences remain protected through Apheris federated infrastructure.
Apheris role · AI recipient · Strategic buyer or operator
- Provider / asset owner — AbbVie, argenx, Lundbeck, Takeda
- AI recipient — Ginkgo Datapoints, Apheris, AbbVie, argenx, Lundbeck, Takeda
- Strategic buyer or operator — Ginkgo Datapoints, Apheris, AbbVie, argenx, Lundbeck, Takeda
Recorded status · active consortium initial dataset expected early 2027. Last reviewed Oct 1, 2026.
Access · training. Training rights · permitted.
Disclosed economics · No membership fee, cash consideration, revenue share, minimum commitment, or asset valuation is disclosed. Members contribute proprietary sequences and receive governed access to consortium data, models, and derivatives for internal use. Scope · Member contributions, assay generation, model-development services, and internal-use benefits are disclosed; transaction value and the allocation of consideration among data, laboratory work, infrastructure, and models are not disclosed.
Evidence
Oct 1, 2025 · Data-rights qualified
AbbVie → AISB Federated OpenFold3 Initiative
Proprietary experimentally determined protein–small molecule structures supplied for federated fine-tuning. This observation records the October 2025 consortium expansion.
Apheris role · AI recipient · Strategic buyer or operator
- Provider / asset owner — AbbVie, Johnson & Johnson, Bristol Myers Squibb, Takeda, Astex Pharmaceuticals
- AI recipient — AISB Federated OpenFold3 Initiative, AlQuraishi Lab, Apheris
- Strategic buyer or operator — AISB Federated OpenFold3 Initiative, AlQuraishi Lab, Apheris
Recorded status · active. Last reviewed Sep 16, 2026.
Access · training, post training. Training rights · permitted.
Disclosed economics · No data-specific consideration disclosed. Scope · not disclosed